Bibliografia UJ CM

1/3
Ludwig Kappos, Mark S. Freedman, Chris H. Polman, Gilles Edan, Hans-Peter Hartung, David H. Miller, Xavier Montalban, Frederik Barkhof, Ernst-Wilhelm Radu, Carola Metzig, Lars Bauer, Vivian Lanius, Rupert Sandbrink, Christoph Pohl, BENEFIT Study Group.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis : 5-year active treatment extension of the phase 3 BENEFIT trial.
Lancet. Neurology
2009 : Vol. 8, nr 11, s. 987-997, il., bibliogr. 41 poz., summ.
p-ISSN: 1474-4422
AZ
ORG
AIF
IF: 18.126
2/3
Ludwig Kappos, Ralf Gold, David H. Miller, Eva Havrdova, Volker Limmroth, Chris H. Polman, Klaus Schmierer, Tarek A. Yousry, Minhua Yang, Mefkure Eraksoy, Ivan Rektor, Katherine D. Dawson, Alfred W. Sandrock, Gilmore N. O'Neill, BG-12 Phase IIb Study Investigators.
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis : a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Lancet
2008 : Vol. 372, nr 9648, s. 1463-1472, il., bibliogr. 36 poz., summ.
AZ
ORG
AIF
IF: 28.409
3/3
Chris H. Polman, Ludwig Kappos, Mark S. Freedman, Gilles Edan, Hans-Peter Hartung, David H. Miller, Xavier Montalban, Frederik Barkhof, Krzysztof Selmaj, Bernard M.J. Uitdehaag, Susanne Dahms, Lars Bauer, Christoph Pohl, Rupert Sandbrink, BENEFIT investigators.
Subgroups of the BENEFIT study : risk of developing MS and treatment effect of interferon beta-1b.
Journal of Neurology
2008 : Vol. 255, nr 4, s. 480-487, bibliogr. 21 poz.
p-ISSN: 0340-5354
AZ
ORG
AIF
IF: 2.536
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ